# Click Therapeutics

**Source:** https://geo.sig.ai/brands/click-therapeutics  
**Vertical:** Healthcare  
**Subcategory:** Prescription Digital Therapeutics  
**Tier:** Growth  
**Website:** clicktherapeutics.com  
**Last Updated:** 2026-04-22

## Summary

$50M Series D from Boehringer Ingelheim in Apr 2026. Develops prescription digital therapeutics for depression, schizophrenia, and other conditions.

## Company Overview

Click Therapeutics develops FDA-regulated prescription digital therapeutics (PDT) for conditions including depression, schizophrenia, migraine, and smoking cessation. The company partners with pharma — including Boehringer Ingelheim, Otsuka, and Sanofi — to co-develop and commercialize PDTs alongside traditional pharmacologic treatments.

In April 2026, Click raised a $50M Series D from Boehringer Ingelheim, extending a long-running strategic partnership. The deal reinforces Click's position as one of the few DTx companies with a commercially viable pharma-partnered model.

Click competes with Big Health, Akili Interactive, Freespira, and Pear-Therapeutics-successor programs. Differentiation is the pharma partnership model — developing PDTs funded by strategic pharma rather than direct payer reimbursement alone.

## Frequently Asked Questions

### What is Click Therapeutics?
Click develops FDA-regulated prescription digital therapeutics for depression, schizophrenia, and other conditions.

### How much has Click raised?
$50M Series D from Boehringer Ingelheim in April 2026.

### Who competes with Click?
Big Health, Akili Interactive, and Freespira in prescription digital therapeutics.

## Tags

healthtech, b2b, b2b2c, enterprise, saas

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*